Celltrion’s STEQEYMA Gains Ground in U.S. as New Products Build on Direct-Sales Network
Celltrion is gaining traction across both new and established biosimilars in the United States, with its newer products increasingly benefiting from the direct-sales network the company has built in the world’s largest pharmaceutical market.According to pharmaceutical market research firm IQVIA, Cel
Celltrion is experiencing growth in the U.S. biosimilars market, with its newer products gaining traction through the direct-sales network the company has established. According to research firm IQVIA, Celltrion's ustekinumab biosimilar STEQEYMA captured 16.2% of the U.S. market in July, rising from a 10.2% share in February. The company attributes this growth to expanded insurance coverage, as STEQEYMA has secured preferred status on formularies of major U.S. pharmacy benefit managers.
YUFLYMA, Celltrion's adalimumab biosimilar, recorded a 9.4% market share in July, expanding its prescription growth after being added to public insurance formularies of two of the three largest PBMs. The company sees potential synergies between its autoimmune disease-targeting products, allowing it to leverage existing relationships with specialists, insurers, and other healthcare stakeholders.
TRUXIMA, a leading rituximab biosimilar with a 38.6% share in July, recently received interchangeability designation from the FDA, making it the first rituximab biosimilar to receive such status. INFLECTRA, Celltrion's infliximab biosimilar, maintains a 30.7% market share. As Celltrion expands its U.S. product lineup, its direct-sales infrastructure is becoming a foundation for its broader portfolio, enabling the company to improve commercial efficiency while increasing its presence across multiple therapeutic areas.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
